Physician profile
Charone Sexton
NPI 1083344980
$820.23
in general payments reported to CMS, 2019-2025
12 companies · $66.81 in 2025
The $66.81 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $313 · 2024: $440 · 2025: $66.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $352.41 | 2023-2025 | |
| Glaxosmithkline, LLC. | $128.91 | 2023-2024 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $60.78 | 2024 | Aptima, Thinprep 2000 Processor |
| Novo Nordisk INC | $50.87 | 2023-2024 | Rybelsus, Ozempic |
| Tactile Systems Technology INC | $41.97 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Astrazeneca Pharmaceuticals LP | $39.81 | 2023-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $37.66 | 2023-2024 | Jardiance, Zepbound, Emgality |
| Exact Sciences Corporation | $26.71 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $25.14 | 2024 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.69 | 2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.99 | 2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $13.29 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charone Sexton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.